A randomized phase IB/IIA study of CApecitabine plus Radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON)

Trial Profile

A randomized phase IB/IIA study of CApecitabine plus Radium-223 (Xofigo) in breast cancer patients with BONe metastases (CARBON)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 14 Jul 2016

At a glance

  • Drugs Capecitabine (Primary) ; Radium 223 chloride (Primary)
  • Indications Breast cancer
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms CARBON
  • Sponsors Bayer HealthCare
  • Most Recent Events

    • 19 May 2016 Status changed from not yet recruiting to recruiting.
    • 07 Apr 2016 Planned initiation date changed from 1 Mar 2015 to 30 May 2016 as per ISRCTN: Current Controlled Trials record.
    • 07 Apr 2016 Status changed from recruiting to not yet recruiting as per ISRCTN: Current Controlled Trials record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top